Skip to content
Search

Latest Stories

Study finds morning exposure to deep red light improves naturally declining eyesight

A pioneering study by UCL researchers has found that just three minutes of exposure to deep red light once a week, when delivered in the morning, can significantly improve declining eyesight.

Published in the journal Scientific Reports, the study builds on the team's previous work, which showed daily three-minute exposure to longwave deep red light 'switched on' energy-producing mitochondria cells in the human retina, helping boost naturally declining vision.


For this latest study, scientists wanted to establish what effect a single three-minute exposure would have, while also using much lower energy levels than their previous studies.

Furthermore, building on separate UCL research in flies that found mitochondria display 'shifting workloads' depending on the time of day, the team compared morning exposure to afternoon exposure.

In summary, researchers found there was, on average, a 17 per cent improvement in participants' colour contrast vision when exposed to three minutes of 670 nanometres (long wavelength) deep red light in the morning and the effects of this single-exposure lasted for at least a week.

However, when the same test was conducted in the afternoon, no improvement was seen.

Scientists say the benefits of deep red light, highlighted by the findings, mark a breakthrough for eye health and should lead to affordable home-based eye therapies, helping millions of people globally with naturally declining vision.

Lead author, Professor Glen Jeffery from UCL Institute of Ophthalmology, said: "We demonstrate that one single exposure to long-wave deep red light in the morning can significantly improve declining vision, which is a major health and wellbeing issue, affecting millions of people globally.

"This simple intervention applied at the population level would significantly impact on quality of life as people age and would likely result in reduced social costs that arise from problems associated with reduced vision."

In humans around 40 years old, cells in the eye's retina begin to age, and the pace of this ageing is caused, in part, when the cell's mitochondria, whose role is to produce energy (known as ATP) and boost cell function, also start to decline.

Mitochondrial density is greatest in the retina's photoreceptor cells, which have high energy demands. As a result, the retina ages faster than other organs, with a 70 per cent ATP reduction over life, causing a significant decline in photoreceptor function as they lack the energy to perform their normal role.

In studying the effects of deep red light in humans, researchers built on their previous findings in mice, bumblebees and fruit flies, which all found significant improvements in the function of the retina's photoreceptors when their eyes were exposed to 670 nanometres (long wavelength) deep red light.

"Mitochondria have specific sensitivities to long-wavelength light influencing their performance: longer wavelengths spanning 650 to 900nm improve mitochondrial performance to increase energy production," said Professor Jeffery.

The retina's photoreceptor population is formed of cones, which mediate colour vision, and rods, which adapt vision in low/dim light. This study focused on cones and observed colour contrast sensitivity, along the protan axis (measuring red-green contrast) and the tritan axis (blue-yellow).

All the participants were aged between 34 and 70, had no ocular disease, completed a questionnaire regarding eye health prior to testing, and had a normal colour vision (cone function).

This was assessed using a 'Chroma Test': identifying coloured letters that had very low contrast and appeared increasingly blurred, a process called colour contrast.

Using a provided LED device all 20 participants (13 female and 7 male) were exposed to three minutes of 670nm deep red light in the morning between 8 am and 9 am. Their colour vision was then tested again three hours post-exposure and 10 of the participants were also tested one-week post-exposure.

On average there was a 'significant' 17 per cent improvement in colour vision, which lasted a week in tested participants; in some older participants there was a 20% improvement, also lasting a week.

A few months on from the first test (ensuring any positive effects of the deep red light had been 'washed out') six (three female, three male) of the 20 participants, carried out the same test in the afternoon, between 12 pm to 1 pm.

When participants then had their colour vision tested again, it showed zero improvements.

Professor Jeffery said, "Using a simple LED device once a week, recharges the energy system that has declined in the retina cells, rather like re-charging a battery.

"And morning exposure is absolutely key to achieving improvements in declining vision: as we have previously seen in flies, mitochondria have shifting work patterns and do not respond in the same way to light in the afternoon - this study confirms this."

For this study, the light energy emitted by the LED torch was just 8mW/cm2, rather than 40mW/cm2, which they had previously used. This has the effect of dimming the light but does not affect the wavelength.

While both energy levels are perfectly safe for the human eye, reducing the energy further is an additional benefit.

With a paucity of affordable deep red-light eye-therapies available, Professor Jeffery has been working for no commercial gain with Planet Lighting UK, a small company in Wales and others, with the aim of producing 670nm infra-red eyewear at an affordable cost, in contrast to some other LED devices designed to improve vision available in the US for over $20,000.

"The technology is simple and very safe; the energy delivered by 670nm long wave light is not that much greater than that found in natural environmental light," Professor Jeffery said.

"Given its simplicity, I am confident an easy-to-use device can be made available at an affordable cost to the general public.

"In the near future, a once a week three-minute exposure to deep red light could be done while making a coffee, or on the commute listening to a podcast, and such a simple addition could transform eye care and vision around the world."

Despite the clarity of the results, researchers say some of the data are "noisy". While positive effects are clear for individuals following 670nm exposure, the magnitude of improvements can vary markedly between those of similar ages. Therefore, some caution is needed in interpreting the data.

It is possible that there are other variables between individuals that influence the degree of improvement that the researchers have not identified so far and would require a larger sample size.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less